title: Influence of inductive chemoradiotherapy on salivary polymorphonuclear leukocyte (SPMN) functions in oral cancer.
abstract: Salivary polymorphonuclear leukocyte (SPMN) functions were examined in 18 patients with oral squamous cell carcinoma and in 20 healthy individuals. SPMN obtained from patients before therapy exhibited significantly less FMLP-stimulated chemotactic activity (132.4 +/- 17.5 cells/0.26 mm2) than that in SPMN from controls (177.1 +/- 11.6 cells/0.26 mm2), although no difference in phagocytosis was observed. When stimulated with PMA or FMLP, control SPMN generated superoxide (O2-) at levels of 50.3 +/- 10.5 pmol/min/10(4) cells and 88.4 +/- 15.4 pmol, respectively, while SPMN from untreated patients generated significantly reduced O2- in the presence of PMA or FMLP (24.3 +/- 3.5 pmol and 59.5 +/- 9.8 pmol, respectively). Only slightly lower chemiluminescence was observed in SPMN from untreated patients however, compared to controls, values being 68.0 +/- 18.9 vs 81.3 +/- 14.9 peak mV by PMA and 62.4 +/- 13.7 vs 64.4 +/- 12.9 peak mV by FMLP. Compared to Candida killing in control subjects (24.9 +/- 3.1%). SPMN from patients before treatment exhibited significantly reduced activity (18.7 +/- 4.9%). Further suppression of the SPMN functions examined was observed after chemoradio-therapy. Suppressed SPMN function in cancer patients, especially that associated with chemoradiotherapy, may therefore play a part in oral candidiasis.
authors: Department of Oral Surgery, Kochi Medical School, Kohasu, Japan.
authors: E
authors: E
authors: Ueta
authors: T
authors: T
authors: Osaki
authors: K
authors: K
authors: Yoneda
authors: T
authors: T
authors: Yamamoto
authors: M
authors: M
authors: Umazume
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002180:Candidiasis, Oral / Q000209:etiology / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000628:therapy; D016022:Case-Control Studies; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000528:radiation effects; D003037:Cobalt Radioisotopes; D003131:Combined Modality Therapy / Q000009:adverse effects; D016371:Cranial Irradiation / Q000009:adverse effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000528:radiation effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects / Q000528:radiation effects; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000150:complications / Q000628:therapy*; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism / Q000528:radiation effects*; D017663:Peplomycin / Q000008:administration & dosage; D010587:Phagocytosis / Q000187:drug effects / Q000528:radiation effects; D012074:Remission Induction; D016897:Respiratory Burst; D012463:Saliva / Q000276:immunology; D013481:Superoxides / Q000378:metabolism
chemical_list: D003037:Cobalt Radioisotopes; D013481:Superoxides; D017663:Peplomycin; D005472:Fluorouracil